After 6 years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level. Issue 6 (December 2015)

• Record Type: Journal Article
• Authors: van Dijk, Peter R.; Logtenberg, Susan J.J.; Chisalita, Simona I.; Hedman, Christina A.; Groenier, Klaas H.; Gans, Reinold O.B.; Kleefstra, Nanne; Arnqvist, Hans J.; Bilo, Henk J.G.
• Is Part Of: Growth hormone & IGF research. Volume 25:Issue 6(2015:Dec.)
• Page Start: 316
• Page End: 319
• Publication Date: 2015-12
• Subjects: IGF-I -- Intraperitoneal insulin -- Type 1 diabetes mellitus; Growth regulators -- Periodicals; Growth -- Regulation -- Periodicals; Somatomedin -- Periodicals; Somatomedins -- Periodicals; Growth Hormone -- Periodicals; Growth Substances -- Periodicals; Croissance -- Régulation -- Périodiques; Croissance -- Régulateurs -- Périodiques; Somatotrophine -- Périodiques; Somatomédine -- Périodiques; Growth -- Regulation; Growth regulators; Electronic journals; Periodicals; Electronic journals; 612.4
• DOI: 10.1016/j.ghir.2015.08.007
• Languages: English
• ISSNs: 1096-6374

Abstract

Abstract: Objective: Low concentrations of insulin-like growth factor-I (IGFI) have been reported in type 1 diabetes mellitus (T1DM), suggested to be due to low insulin concentrations in the portal vein. The aim was to describe the long-term course of IGFI concentrations among T1DM subjects treated with continuous intraperitoneal (IP) insulin infusion (CIPII). Design: Nineteen patients that participated in a randomized cross-over trial comparing CIPII and subcutaneous (SC) insulin therapy in 2006 were followed until 2012. IGF-I measurements were performed at the start of the 2006 study, after the 6 month SC- and CIPII treatment phase in 2006 and during CIPII therapy in 2012. Z-scores were calculated to compare the IGF-I concentrations with age-specific normative range values of a non-DM reference population. Results: In 2012, IGF-I Z-scores (− 0.7; 95% confidence interval − 1.3, − 0.2) were significantly higher than at the start of the 2006 study (− 2.5; − 3.3, − 1.8), the end of the SC (− 2.0; − 2.6, − 1.5) and CIPII (− 1.6; − 2.1, − 1.0) treatment phase with a mean difference of: 1.8 (0.9, 2.7), 1.3 (0.5, 2.1) and 0.8 (0.1, 1.6), respectively. Conclusion: After 6 years of treatment with CIPII, IGF-I concentrations among T1DM patients increased to a level that is higher than during prior SC insulin treatment and is in the lower normal range compared to a non-DM reference population. The results of this study suggest that long-term IP insulin administration influences the IGF system in T1DM. Highlights: This study describes the effect of continuous intraperitoneal insulin infusion (CIPII) on IGF1 concentrations in type 1 diabetes mellitus. After 6 years of CIPII, IGF1 concentrations increased to a higher level than during prior subcutaneous insulin treatment. These IGF1 levels are in the lower normal range compared to a non-diabetes reference population. This study suggests that long-term intraperitoneal insulin administration influences the IGF system in T1DM.